Related references
Note: Only part of the references are listed.Remission of persistent methamphetamine-induced psychosis after cariprazine therapy: presentation of a case report
Valerio Ricci et al.
JOURNAL OF ADDICTIVE DISEASES (2022)
Comparative Efficacy and Tolerability of Antipsychotics for Juvenile Psychotic Disorders A Systematic Review and Network Meta-Analysis
Caitlin S. Yee et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2022)
Systematic Review and Network Meta-analysis: Efficacy and Safety of Second-Generation Antipsychotics in Youths With Bipolar Depression
Melissa P. DelBello et al.
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY (2022)
Case series: Cariprazine for treatment of methamphetamine use disorder
Thanh Thuy Truong et al.
AMERICAN JOURNAL ON ADDICTIONS (2022)
Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: the EU-GEI case-control study
Diego Quattrone et al.
PSYCHOLOGICAL MEDICINE (2021)
Cannabis use disorder and dissociation: A report from a prospective first-episode psychosis study
V Ricci et al.
DRUG AND ALCOHOL DEPENDENCE (2021)
Duration of Untreated Disorder and Cannabis Use: An Observational Study on a Cohort of Young Italian Patients Experiencing Psychotic Experiences and Dissociative Symptoms
Valerio Ricci et al.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2021)
Efficacy and safety of lurasidone in adolescents and young adults with schizophrenia: A pooled post hoc analysis of double-blind, placebo-controlled 6-week studies
Isabella Costamagna et al.
EUROPEAN PSYCHIATRY (2021)
Cannabis use and psychosis: a review of reviews
Alkomiet Hasan et al.
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE (2020)
Major depressive disorder with mixed features and treatment response to lurasidone: A symptom network model
Joseph F. Goldberg et al.
JOURNAL OF AFFECTIVE DISORDERS (2020)
Cannabis and mental illness: a review
Darby J. E. Lowe et al.
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE (2019)
Association of Pre-onset Subthreshold Psychotic Symptoms With Longitudinal Outcomes During Treatment of a First Episode of Psychosis
Rachel J. Rosengard et al.
JAMA PSYCHIATRY (2019)
The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study
Marta Di Forti et al.
LANCET PSYCHIATRY (2019)
Rates and Predictors of Conversion to Schizophrenia or Bipolar Disorder Following Substance-Induced Psychosis
Marie Stefanie Kejser Starzer et al.
AMERICAN JOURNAL OF PSYCHIATRY (2018)
Clinical characteristics of primary psychotic disorders with concurrent substance abuse and substance-induced psychotic disorders: A systematic review
Lorna Wilson et al.
SCHIZOPHRENIA RESEARCH (2018)
Efficacy of lurasidone in the treatment of agitation: A post hoc analysis of five short-term studies in acutely ill patients with schizophrenia
Michael H. Allen et al.
GENERAL HOSPITAL PSYCHIATRY (2017)
Symptomatic and functional outcomes of substance use disorder persistence 2 years after admission to a first-episode psychosis program
Amal Abdel-Baki et al.
PSYCHIATRY RESEARCH (2017)
Poor medication adherence and risk of relapse associated with continued cannabis use in patients with first-episode psychosis: a prospective analysis
Tabea Schoeler et al.
LANCET PSYCHIATRY (2017)
A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia
Rajiv Tandon et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2016)
Cannabis Use Is Associated With Increased Psychotic Symptoms and Poorer Psychosocial Functioning in First-Episode Psychosis: A Report From the UK National EDEN Study
Jennifer L. Seddon et al.
SCHIZOPHRENIA BULLETIN (2016)
Comment on An Open Trial of Lurasidone as an Acute and Maintenance Adjunctive Treatment for Outpatients With Treatment-Resistant Bipolar Disorder
Ian Ross McGrane et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2016)
Premorbid cannabis use is associated with more symptoms and poorer functioning in schizophrenia spectrum disorder
P. A. Ringen et al.
PSYCHOLOGICAL MEDICINE (2016)
Meta-analysis of the Association Between the Level of Cannabis Use and Risk of Psychosis
Arianna Marconi et al.
SCHIZOPHRENIA BULLETIN (2016)
Differential effects of childhood trauma and cannabis use disorders in patients suffering from schizophrenia
G. Baudin et al.
SCHIZOPHRENIA RESEARCH (2016)
Traditional marijuana, high-potency cannabis and synthetic cannabinoids: increasing risk for psychosis
Robin M. Murray et al.
WORLD PSYCHIATRY (2016)
Association of cannabis use with hospital admission and antipsychotic treatment failure in first episode psychosis: an observational study
Rashmi Patel et al.
BMJ OPEN (2016)
Course of cannabis use and clinical outcome in patients with non-affective psychosis: a 3-year follow-up study
F. J. van der Meer et al.
PSYCHOLOGICAL MEDICINE (2015)
A systematic review of the antipsychotic properties of cannabidiol in humans
Tabitha A. Iseger et al.
SCHIZOPHRENIA RESEARCH (2015)
Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo-controlled studies
Henry A. Nasrallah et al.
CNS SPECTRUMS (2015)
Pharmacological treatments for drug misuse and dependence
Kylie Reed et al.
EXPERT OPINION ON PHARMACOTHERAPY (2015)
Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study
Marta Di Forti et al.
LANCET PSYCHIATRY (2015)
Lurasidone Monotherapy in the Treatment of Bipolar I Depression: A Randomized, Double-Blind, Placebo-Controlled Study
Antony Loebel et al.
AMERICAN JOURNAL OF PSYCHIATRY (2014)
Future pharmacological treatments for substance use disorders
Ariadna Forray et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Aripiprazole for Treating Cannabis-Induced Psychotic Symptoms in Ultrahigh-Risk Individuals
Benjamin Rolland et al.
CLINICAL NEUROPHARMACOLOGY (2013)
Lurasidone for the treatment of acutely psychotic patients with schizophrenia: A 6-week, randomized, placebo-controlled study
Henry A. Nasrallah et al.
JOURNAL OF PSYCHIATRIC RESEARCH (2013)
Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study
Masaaki Ogasa et al.
PSYCHOPHARMACOLOGY (2013)
Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: A randomized, double-blind, placebo- and active-controlled trial
Antony Loebel et al.
SCHIZOPHRENIA RESEARCH (2013)
Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: A 12-month, double-blind, noninferiority study
Antony Loebel et al.
SCHIZOPHRENIA RESEARCH (2013)
The Association between Cannabis Use and Earlier Age at Onset of Schizophrenia and other Psychoses: Meta-analysis of Possible Confounding Factors
Nicholas Myles et al.
CURRENT PHARMACEUTICAL DESIGN (2012)
Prevalence and impact of cannabis use disorders in adolescents with early onset first episode psychosis
B. G. Schimmelmann et al.
EUROPEAN PSYCHIATRY (2012)
Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study
Leslie Citrome et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2012)
Measures of Substance Consumption Among Substance Users, DSM-IV Abusers, and Those With DSM-IV Dependence Disorders in a Nationally Representative Sample
Howard B. Moss et al.
JOURNAL OF STUDIES ON ALCOHOL AND DRUGS (2012)
The Effect of Cannabis Use and Cognitive Reserve on Age at Onset and Psychosis Outcomes in First-Episode Schizophrenia
Verity C. Leeson et al.
SCHIZOPHRENIA BULLETIN (2012)
Lurasidone in the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo- and Olanzapine-Controlled Study
Herbert Y. Meltzer et al.
AMERICAN JOURNAL OF PSYCHIATRY (2011)
Pharmacological Profile of Lurasidone, a Novel Antipsychotic Agent with Potent 5-Hydroxytryptamine 7 (5-HT7) and 5-HT1A Receptor Activity
Tadashi Ishibashi et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2010)
Lurasidone in the Treatment of Acute Schizophrenia: A Double-Blind, Placebo-Controlled Trial
Mitsutaka Nakamura et al.
JOURNAL OF CLINICAL PSYCHIATRY (2009)
Cannabis use in children and adolescents with first episode psychosis: Influence on psychopathology and short-term outcome (CAFEPS study)
Immaculada Baeza et al.
SCHIZOPHRENIA RESEARCH (2009)
The natural course of cannabis use, abuse and dependence during the first decades of life
Axel Perkonigg et al.
ADDICTION (2008)
Cannabis and psychosis
Daniele Fabio Zullino et al.
LANCET (2007)
Pre-treatment, baseline, and outcome differences between early-onset and adult-onset psychosis in an epidemiological cohort of 636 first-episode patients
Benno G. Schimmelmann et al.
SCHIZOPHRENIA RESEARCH (2007)
The environment and schizophrenia: The role of cannabis use
C Henquet et al.
SCHIZOPHRENIA BULLETIN (2005)
Cannabis as a risk factor for psychosis: systematic review
DM Semple et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2005)
Cannabis use and psychosis: A longitudinal population-based study
J van Os et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2002)
Share Paper
